Comparative Analysis of Cytomorphological and Histomorphological Characteristics of Thyroid Nodules: Correlation of FNA AUS/FLUS Category With the Definitive Histopathological Diagnosis

Authors

  • Aleksandra Oluški Faculty of Medicine, University of Novi Sad Author
  • Filip Kapor Faculty of Medicine, University of Novi Sad Author

Keywords:

thyroid nodules, AUS/FLUS, FNA, cytomorphology, malignancy

Abstract

Introduction: Thyroid nodules are a common finding in clinical practice, and fine-needle aspiration (FNA) combined with the Bethesda classification is crucial for assessing malignancy risk. Category III (AUS/FLUS) remains a diagnostic challenge due to heterogeneous cytomorphological features and uncertain malignancy risk.

The aim: To analyze the cytomorphological characteristics of FNA samples from thyroid nodules classified as AUS/FLUS in correlation with final histopathological results, aiming to assess their diagnostic value.

Materials and Methods: A retrospective analysis was performed on 67 nodules from 44 patients categorized as AUS/FLUS and surgically removed. Cytological features, atypia subtypes (nuclear, architectural, Hürthle-dominant), and a cumulative nuclear score were evaluated, with the discriminative ability of the score assessed by ROC analysis.

Results: Among 67 nodules, 49 (73%) were benign and 18 (27%) malignant. Individual cytological features did not significantly predict malignancy. The cumulative nuclear score demonstrated moderate discriminative ability (AUC 0.72). Dominant atypia subtype did not significantly differentiate risk, although observed trends may inform future research and refine cytological predictors.

Conclusion: AUS/FLUS thyroid nodules remain a diagnostic challenge due to cytomorphological heterogeneity. Individual cytological features were not statistically predictive of malignancy, whereas the cumulative nuclear score represents a potential tool for risk assessment. Detailed cytomorphological evaluation combined with the nuclear score may support clinical decision-making, including repeat FNA, molecular testing, or surgical intervention, improving the safety and efficiency of nodule management.

Published

2026-11-18

Issue

Section

Abstracts